MoleSafe Showcases Mole Monitoring Technology to Aid Early Melanoma Diagnosis at 71st Annual American Academy of Dermatology Meeting

MoleSafe USA, the world’s most advanced melanoma screening program, will showcase its suite of advanced melanoma detection and diagnosis  tools and technology at the 71^st American Academy of Dermatology (AAD) Annual Meeting, in Miami Beach, Fla., March 1 to March 5, 2013. MoleSafe’s innovative program results in earlier detection of melanoma and reduces the unnecessary removal of benign lesions. The comprehensive program incorporates total body photography, digital dermoscopy, and digital serial monitoring. MoleSafe will showcase these important technologies at booth 2454 during the AAD’s Annual Meeting, the world’s largest and most comprehensive dermatologic educational event.

The MoleSafe program includes total body photography, which creates a complete record of the skin to identify new moles and pick up subtle changes in existing moles, key factors in detecting melanoma in at-risk patients – patients with dysplastic nevus syndrome, patients with 50 or more moles, patients with a history of melanoma, patients with a family history of melanoma, people who have had transplants and have been on immunosuppressive medications, people who have naturally light hair, light skin and/or light eyes, people who use indoor tanning salons, and people who have suffered one or more severe blistering sunburn(s) as an adolescent.

MoleSafe’s use of digital dermoscopy combines painless high magnification and high light intensity to illuminate sub-surface features and lesions that cannot be observed with the naked eye. Dermoscopy enhances the diagnostic accuracy for melanoma and helps to reduce the need for unnecessary biopsies by 80 percent. The results are digital, in high resolution, and are quickly interpreted by some of the world's leading experts in dermoscopy. These experts flag hundreds of melanoma cases each year, compared to a dermatologist who will only see a handful.

MoleSafe also uses serial digital monitoring to track moles of all its patients, helping to identify moles that are changing and moles that are stable and have not changed. The MoleSafe program continues to use advanced technology to increase its accuracy of detecting melanoma at the earliest stage possible, and has recently implemented the use of the On-line View application, allowing MoleSafe’s physicians to view their patient information from the DX report, total body photography and all clinical and dermoscopic images of the moles, on their portable devises, including iPads, iPhones, and/or laptops. This information is seamlessly integrated into the patient’s visit, providing a high quality of care.

“Just as women receive yearly mammograms to detect for breast cancer, early detection melanoma screening programs help to significantly lower your risk of dying from melanoma skin cancer, diagnoses melanoma at its earliest possible stage, and reduce the number of unnecessary biopsies and procedures,” said Richard Bezozo, M.D. President of MoleSafe. “We will be illustrating the power and effectiveness of our suite of early detection technologies in our booth at the AAD meeting, providing a hands-on demonstration of the ease-of-use and the quality of the images we can obtain to significantly both men and women’s chances of survival from melanoma.”

Each year, thousands of clinicians, experts and organizations in the dermatology field attend the AAD Annual Meeting to showcase their latest findings and advancements. MoleSafe will be exhibiting at booth 2454 at the AAD meeting. For more information on MoleSafe, please visit www.molesafe.com, or its Facebook page at http://www.facebook.com/molesafe.

About MoleSafe Inc.

MoleSafe/MoleMap is a global leader in development and provision of unique, proven, integrated imaging and teledermatology health solutions for early and accurate detection of skin cancer.  Today 40 clinics have been established in the U.S., New Zealand, and Australia and thousands of melanomas and other skin cancers have been diagnosed from more than 150,000 telemedicine consultations.  For more information about MoleSafe, please visit www.molesafe.com